Canadian psychedelics biotech Tryp Therapeutics Inc. has entered into an agreement with Australian publicly-trading drug vehicle developer Exopharm Ltd. for the acquisition of 100% of Tryp’s issued and outstanding common shares. The arm’s length transaction, dated Dec. 8, 2023, will be completed as a statutory plan of arrangement under the BC Business Corporations Act. What To KnowVoting, Managerial Comments & AdvisorsFollowing an “extensive and robust” review of strategic alternatives for maximizing shareholder value, Tryp’s board of directors and a special committee are unanimously recommend…